Identification
Name3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
Accession NumberDB07179
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS numberNot Available
WeightAverage: 410.267
Monoisotopic: 409.053822806
Chemical FormulaC19H16BrN5O
InChI KeyDXUJQXZHHGJMFM-UHFFFAOYSA-N
InChI
InChI=1S/C19H16BrN5O/c1-13-5-2-3-7-15(13)17-9-18(25-19(23-17)16(20)11-22-25)21-10-14-6-4-8-24(26)12-14/h2-9,11-12,21H,10H2,1H3
IUPAC Name
3-({[3-bromo-5-(2-methylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino}methyl)pyridin-1-ium-1-olate
SMILES
CC1=C(C=CC=C1)C1=NC2=C(Br)C=NN2C(NCC2=C[N+]([O-])=CC=C2)=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Cyclin-dependent kinase 2ProteinunknownNot AvailableHumanP24941 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00318 mg/mLALOGPS
logP3.07ALOGPS
logP2.78ChemAxon
logS-5.1ALOGPS
pKa (Strongest Basic)1.91ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area67.68 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity116.79 m3·mol-1ChemAxon
Polarizability39.5 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9756
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.6052
P-glycoprotein inhibitor INon-inhibitor0.77
P-glycoprotein inhibitor IIInhibitor0.7871
Renal organic cation transporterNon-inhibitor0.7158
CYP450 2C9 substrateNon-substrate0.74
CYP450 2D6 substrateNon-substrate0.8125
CYP450 3A4 substrateSubstrate0.5691
CYP450 1A2 substrateInhibitor0.8165
CYP450 2C9 inhibitorInhibitor0.5559
CYP450 2D6 inhibitorNon-inhibitor0.8524
CYP450 2C19 inhibitorInhibitor0.6465
CYP450 3A4 inhibitorInhibitor0.5929
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9184
Ames testAMES toxic0.5283
CarcinogenicityNon-carcinogens0.8198
BiodegradationNot ready biodegradable0.995
Rat acute toxicity2.5089 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.632
hERG inhibition (predictor II)Non-inhibitor0.6143
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassDiazines
Direct ParentPhenylpyrimidines
Alternative ParentsPyrazolo[1,5-a]pyrimidines / Toluenes / Secondary alkylarylamines / Aminopyrimidines and derivatives / Pyridinium derivatives / Aryl bromides / Pyrazoles / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds
Substituents4-phenylpyrimidine / 5-phenylpyrimidine / Pyrazolo[1,5-a]pyrimidine / Pyrazolopyrimidine / Aminopyrimidine / Toluene / Secondary aliphatic/aromatic amine / Aryl bromide / Aryl halide / Monocyclic benzene moiety
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Metal ion binding
Specific Function:
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Interacts with cyclins A, B1, B3, D, or E. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synt...
Gene Name:
CDK2
Uniprot ID:
P24941
Molecular Weight:
33929.215 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Drug created on September 15, 2010 15:19 / Updated on June 11, 2017 21:05